NCT00085410终止2 期
Phase II and Pharmacodynamic Study of PS-341 in Patients With Unresectable or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Objective Response Rate
研究概览
简要总结
This phase II trial is studying how well bortezomib works as first-line systemic therapy in treating patients with unresectable locally advanced or metastatic adenocarcinoma (cancer) of the bile duct or gallbladder. Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
详细描述
PRIMARY OBJECTIVES:
I. Determine the objective response rate in patients with unresectable locally advanced or metastatic adenocarcinoma of the bile duct or gallbladder treated with bortezomib.
SECONDARY OBJECTIVES:
I. Determine the time to disease progression in patients treated with this drug.
II. Determine the overall survival of patients treated with this drug. III. Correlate the degree of proteasome inhibition in peripheral blood with degree of proteasome inhibition in tumor specimens of patients treated with this drug.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Absolute neutrophil count >= 1,500/mm3
- •No psychiatric illness or social situation that would preclude study compliance
- •Chemotherapy administered solely as a radiosensitizer or as adjuvant therapy and investigational or targeted therapies (i.e., inhibitors of the epidermal growth factor receptor) will not count toward the maximum of 2 prior regimens allowed
- •Histologically or cytologically confirmed adenocarcinoma of the intrahepatic or extrahepatic bile duct or gallbladder:
- •Locally advanced or metastatic disease
- •At least 1 unidimensionally measurable lesion >=20 mm by conventional techniques OR >= 10 mm by spiral CT scan
- •Not amenable to curative surgical resection
- •No known brain metastases
- •Performance status:
- •Life expectancy:
- •More than 12 weeks
- •Platelet count >= 100,000/mm3
- •WBC >= 3,000/mm3
- •AST and ALT ≤ 2.5 times upper limit of normal (ULN) [Note: Biliary shunting or stenting allowed to achieve the required bilirubin and transaminase levels]
- •Bilirubin ≤ 1.5 times ULN [Note: Biliary shunting or stenting allowed to achieve the required bilirubin and transaminase levels]
- •Creatinine within ULN OR Creatinine clearance >= 60 mL/min
- •No symptomatic congestive heart failure
- •No unstable angina pectoris
- •No symptomatic cardiac arrhythmia within the past 4 weeks
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception
- •No underlying neuropathy >= grade 2
- •No history of allergic reaction to boron, mannitol, or bortezomib
- •No active or ongoing infection
- •No concurrent uncontrolled illness
- •No medical or psychiatric condition that would preclude study participation
- •No prophylactic granulocyte or platelet growth factors (filgrastim [G-CSF] or sargramostim [GM-CSF])
- •Prior chemotherapy as a radiosensitizer (e.g., fluorouracil or gemcitabine) with radiotherapy is allowed as adjuvant therapy after resection for locally advanced disease provided there is evidence of disease progression
- •No more than 2 prior chemotherapy regimens for locally advanced or metastatic disease
- •No concurrent combination antiretroviral therapy for HIV-positive patients
- •No other concurrent anticancer agents or therapies
- •No other concurrent investigational agents
排除标准
- 未提供
研究组 & 干预措施
Arm I
Experimental
Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11.
干预措施: bortezomib (Drug)
结局指标
主要结局
Objective Response Rate
时间窗: Up to 1 year
Objective Response Rate (ORR) was determined by best response on radiologic assessment (computed tomography or magnetic resonance imaging) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.0.
次要结局
- Correlation of the Degree of Proteasome Inhibition in Peripheral Blood With the Degree of Proteasome Inhibition in Tumor Specimens(Once in the screening period (within 14 days of starting treatment))
- Time to Disease Progression(Up to 1 year)
- Overall Survival(Up to 1 year)
- Correlation of Phenotypic Expression of NF-kB, p53, and Other Molecular Markers in Biliary Washings and Tumor Biopsies With Clinical Outcomes(Once in the screening period (within 14 days of starting treatment))
- Correlation of Treatment With Changes in Phenotypic Expression of Molecular Markers(Duration of study treatment)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and NeckRecurrent Adenoid Cystic Carcinoma of the Oral CavityRecurrent Salivary Gland CancerSalivary Gland Adenoid Cystic CarcinomaStage III Adenoid Cystic Carcinoma of the Oral CavityStage III Salivary Gland CancerStage IV Adenoid Cystic Carcinoma of the Oral CavityStage IV Salivary Gland CancerNCT00077428National Cancer Institute (NCI)37
已完成
2 期
Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung CancerAdenocarcinoma of the LungBronchoalveolar Cell Lung CancerRecurrent Non-small Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung CancerNon-small Cell Lung CancerNCT00118144National Cancer Institute (NCI)42
已完成
2 期
Bortezomib in Treating Patients With Newly Diagnosed Multiple MyelomaStage I Multiple MyelomaStage II Multiple MyelomaStage III Multiple MyelomaNCT00075881National Cancer Institute (NCI)44
已完成
2 期
Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or StomachAdenocarcinoma of the Gastroesophageal JunctionDiffuse Adenocarcinoma of the StomachIntestinal Adenocarcinoma of the StomachMixed Adenocarcinoma of the StomachRecurrent Gastric CancerStage IIIB Gastric CancerStage IIIC Gastric CancerStage IV Gastric CancerNCT00061932National Cancer Institute (NCI)41
已完成
2 期
Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid LeukemiaAdult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myelomonocytic Leukemia (M4)Childhood Acute Basophilic LeukemiaChildhood Acute Eosinophilic LeukemiaChildhood Acute Erythroleukemia (M6)Childhood Acute Megakaryocytic Leukemia (M7)Childhood Acute Minimally Differentiated Myeloid Leukemia (M0)Childhood Acute Monoblastic Leukemia (M5a)Childhood Acute Monocytic Leukemia (M5b)Childhood Acute Myeloblastic Leukemia With Maturation (M2)Childhood Acute Myeloblastic Leukemia Without Maturation (M1)Childhood Acute Myelomonocytic Leukemia (M4)Recurrent Adult Acute Myeloid LeukemiaRecurrent Childhood Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaNCT00666588National Cancer Institute (NCI)52